Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

IMPACT-AFib: Single mailing fails to budge oral anticoagulant uptake for AFib

Key clinical point: A single educational mailing sent to patients with atrial fibrillation who were candidates for oral anticoagulation, but had not yet started a regimen, failed to get them started on an antithrombotic regimen.

Major finding: By 1 year following the intervention, 10% of patients in both the intervention and a control arm of the randomized trial had begun treatment.

Study details: IMPACT-AF was a randomized trial of more than 47,000 atrial fibrillation patients who had not adopted an antithrombotic regimen.

Disclosures: IMPACT-AFib received no commercial funding, and Dr. Pokorney and Dr. Shivkumar had no disclosures. Dr. Leclercq has received honoraria from Abbott, Biotronik, Boston Scientific, Livanova, and Medtronic.